scholarly journals WITHDRAWN (By Publisher): Letter to the Editor: Protective Role of Skeletal Muscle Mass Against Progression From Metabolically Healthy to Unhealthy Phenotype

2019 ◽  
Vol 104 (8) ◽  
pp. W1-W3
Author(s):  
Jean-Christophe Lagacé ◽  
Dominic Tremblay ◽  
Jasmine Paquin ◽  
Alexis Marcotte-Chénard ◽  
Eléonor Riesco ◽  
...  
2018 ◽  
Vol 90 (1) ◽  
pp. 102-113 ◽  
Author(s):  
Min Jung Lee ◽  
Eun-Hee Kim ◽  
Sung-Jin Bae ◽  
Jaewon Choe ◽  
Chang Hee Jung ◽  
...  

2020 ◽  
Vol 21 (5) ◽  
pp. 1628 ◽  
Author(s):  
Keisuke Hitachi ◽  
Masashi Nakatani ◽  
Shiori Funasaki ◽  
Ikumi Hijikata ◽  
Mizuki Maekawa ◽  
...  

Skeletal muscle is a highly plastic organ that is necessary for homeostasis and health of the human body. The size of skeletal muscle changes in response to intrinsic and extrinsic stimuli. Although protein-coding RNAs including myostatin, NF-κβ, and insulin-like growth factor-1 (IGF-1), have pivotal roles in determining the skeletal muscle mass, the role of long non-coding RNAs (lncRNAs) in the regulation of skeletal muscle mass remains to be elucidated. Here, we performed expression profiling of nine skeletal muscle differentiation-related lncRNAs (DRR, DUM1, linc-MD1, linc-YY1, LncMyod, Neat1, Myoparr, Malat1, and SRA) and three genomic imprinting-related lncRNAs (Gtl2, H19, and IG-DMR) in mouse skeletal muscle. The expression levels of these lncRNAs were examined by quantitative RT-PCR in six skeletal muscle atrophy models (denervation, casting, tail suspension, dexamethasone-administration, cancer cachexia, and fasting) and two skeletal muscle hypertrophy models (mechanical overload and deficiency of the myostatin gene). Cluster analyses of these lncRNA expression levels were successfully used to categorize the muscle atrophy models into two sub-groups. In addition, the expression of Gtl2, IG-DMR, and DUM1 was altered along with changes in the skeletal muscle size. The overview of the expression levels of lncRNAs in multiple muscle atrophy and hypertrophy models provides a novel insight into the role of lncRNAs in determining the skeletal muscle mass.


Aging Cell ◽  
2015 ◽  
Vol 14 (4) ◽  
pp. 511-523 ◽  
Author(s):  
Adam P. Sharples ◽  
David C. Hughes ◽  
Colleen S. Deane ◽  
Amarjit Saini ◽  
Colin Selman ◽  
...  

Author(s):  
Hiroshi Fukushima ◽  
Kosuke Takemura ◽  
Hiroaki Suzuki ◽  
Fumitaka Koga

Sarcopenia, the degenerative and systemic loss of skeletal muscle mass, indicates patient frailty and impaired physical function. Sarcopenia can be caused by multiple factors, including advanced age, lack of exercise, poor nutritional status, inflammatory diseases, endocrine diseases, and malignancies. Recently, growing evidence has indicated the importance of sarcopenia in the management of patients with various cancers. Sarcopenia is associated with not only higher rates of treatment-related complications but also worse prognosis in cancer-bearing patients. In this article, we conducted a systematic literature review regarding the significance of sarcopenia as a prognostic biomarker of bladder cancer. We also reviewed recent studies focusing on the prognostic role of changes in skeletal muscle mass during the course of treatment in bladder cancer patients.


Sign in / Sign up

Export Citation Format

Share Document